Pharmaxis receives approval for phase 2 study of its cancer drug in liver cancer
9th
Nov 21
Release Date: 09/11/2021 10:00am
Pharmaxis CEO Gary Phillips speaks to Proactive following the news an Investigational New Drug application for a trial of PXS‐5505 in hepatocellular carcinoma (HCC) patients has been cleared by the FDA. The IND was submitted by the University of Rochester Medical Center following positive pre‐clinical results reported in August.
Watch the interview here
Categories: Video Content